首页> 美国卫生研究院文献>other >Current Trends in West Nile Virus Vaccine Development
【2h】

Current Trends in West Nile Virus Vaccine Development

机译:西尼罗河病毒疫苗开发的最新趋势

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

West Nile virus (WNV) is a mosquito-borne flavivirus that has become endemic in the United States. From 1999-2012, there have been 37,088 reported cases of WNV and 1,549 deaths, resulting in a 4.2% case-fatality rate. Despite development of effective WNV vaccines for horses, there is no vaccine to prevent human WNV infection. Several vaccines have been tested in preclinical studies and to date there have been 8 clinical trials, with promising results in terms of safety and induction of antiviral immunity. Although mass vaccination is unlikely to be cost-effective, implementation of a targeted vaccine program may be feasible if a safe and effective vaccine can be brought to market. Further evaluation of new and advanced vaccine candidates is strongly encouraged.
机译:西尼罗河病毒(WNV)是一种蚊子传播的黄病毒,已在美国流行。从1999年至2012年,已报告37,088例WNV病例,死亡1,549例,病死率为4.2%。尽管已开发出有效的马WNV疫苗,但尚无可预防人类WNV感染的疫苗。几种疫苗已在临床前研究中进行了测试,迄今为止已进行了8项临床试验,在安全性和诱导抗病毒免疫方面取得了可喜的结果。尽管大规模疫苗接种不太可能具有成本效益,但如果可以将安全有效的疫苗推向市场,则实施有针对性的疫苗计划可能是可行的。强烈建议对新的和先进的疫苗候选者进行进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号